15-Year study to uncover hidden heart risks of common breast cancer drugs
NCT ID NCT05078190
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 200 women with breast cancer who are receiving doxorubicin and/or trastuzumab. Researchers want to learn how these drugs affect the heart over time and how factors like race, income, and access to healthcare play a role. Participants will have heart ultrasounds, blood tests, and answer questions about their health for up to 15 years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Can better healthcare access save hearts after prison?
- Radiation may let breast cancer patients keep their nipple